NCT06708858View on ClinicalTrials.gov

Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2027

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

Surufatinib

200mg，qd，po

DRUG

Gemcitabine

1000mg/ m2, IV，d1，8，q3w

DRUG

Cisplatin

25mg/m2，IV，d1，8，q3w

DRUG

Durvalumab

1500mg，IV，d1，q3w

DRUG

Pembrolizumab

200mg，IV，d1，q3w

Trial Locations (1)

Unknown

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Dai, Guanghai

OTHER